ISLMF.US InSilico Medicine Cayman TopCo
- Market cap
- -
- P/E
- -
- P/B
- 5.11x
- ROE
- -77.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ISLMF.US undervalued?
Graham numberThe Graham number of InSilico Medicine Cayman TopCo cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InSilico Medicine Cayman TopCo fundamental analysis
No fundamental analysis for InSilico Medicine Cayman TopCo yet.
InSilico Medicine Cayman TopCo stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The comp…
Full company profileInSilico Medicine Cayman TopCo financial statements
InSilico Medicine Cayman TopCo annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 30.1M | 51.2M | 85.8M | 56.2M |
| Gross Profit | 19.1M | 38.6M | 77.6M | 45.8M |
| Operating Income | -79.8M | -89.9M | -33.4M | -62.0M |
| EBITDA | -220M | -207M | -10.8M | -347M |
| Net Income | -222M | -212M | -17.1M | -352M |
| EPS | -0.40 | -0.38 | -0.03 | -0.63 |
| Balance Sheet | ||||
| Total Assets | 235M | 203M | 144M | 490M |
| Total Liabilities | 684M | 853M | 808M | 38.0M |
| Shareholders' Equity | -450M | -650M | -664M | 452M |
| Cash & Short-term Investments | 208M | 177M | 126M | 393M |
| Cash Flow | ||||
| Operating Cash Flow | -47.5M | -29.6M | -57.4M | -76.8M |
| Capital Expenditure | 11.2M | 2.97M | 925K | 2.98M |
| Free Cash Flow | -58.7M | -32.5M | -58.3M | -79.7M |
| Ratios | ||||
| ROE | - | - | - | -77.9% |
| ROA | -94.5% | -104.4% | -11.9% | -71.9% |
| Net Profit Margin | -735.8% | -413.5% | -19.9% | -626.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
InSilico Medicine Cayman TopCo dividends
InSilico Medicine Cayman TopCo has not paid dividends in the last 4 fiscal years.
Who owns InSilico Medicine Cayman TopCo
- Insiders 7.83%
- Institutions 31.08%
- Public & others 61.09%
- Free float 503M
InSilico Medicine Cayman TopCo company profile
- Company name
- InSilico Medicine Cayman TopCo
- Ticker
- ISLMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 333
- Fiscal year end
- December
- Address
- Building 8W, Phase 2, Hong Kong, Hong Kong
- Website
- insilico.com
About InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. InSilico Medicine Cayman TopCo has a strategic collaboration agreement with Takeda to use its proprietary Pharma.AI, to advance drug candidates; and collaboration with Servier for researching and developing programs for oncology. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
InSilico Medicine Cayman TopCo management
7- Dr. Aleksandrs Zhavoronkov Ph.D.Founder, CEO, Chief Business Officer, Longevity Board Member & Chairman of the Board · born 1980
- Dr. Feng Ren Ph.D.CO-CEO, Chief Scientific Officer, Longevity Board Member & Executive Director · born 1975
- Mr. Peng DaiVP & Head of Finance · born 1985
- Mr. Aleksandr Aliper Ph.D.President · born 1990
- Dr. Xiao DingHead of Chemistry
- Dr. Man ZhangHead of Biology
- Ms. Kwan Wai LeungCompany Secretary · born 1983